Andrew Stewart Poklepovic, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Virginia Commonwealth University School Of Medicine (Previously MCV) - Richmond VA
Rank: Assistant Professor
Years: 2007-2008, 2011-Present

None Reported

Population-based risk factors and resource utilization for HCC: US perspective.
Current Medical Research Opinion
Date: 09 2010
www.ncbi.nlm.nih.gov/pubmed/20666689

PARP1 Modulates the Lethality of CHK1 Inhibitors in Mammary Tumors.
Molecular Pharmacology
Date: 05 2012
www.ncbi.nlm.nih.gov/pubmed/22596349

Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
Cancer Biology and Therapeutics
Date: 05 2012
www.ncbi.nlm.nih.gov/pubmed/22406992

Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.
Cancer Biology and Therapeutics
Date: 07 2012
www.ncbi.nlm.nih.gov/pubmed/22673740

Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.
oncotarget
Date: 05 2016

Phase I Cancer Trials and Palliative Care: Antagonism, Irrelevance, or Synergy?
J Pain Symptom Manage
Date: 05 2016

Phase I study of pemetrexed with sorafenib in advanced solid tumors.
Oncotarget.
Date: 05 2016

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Oncotarget
Date: 03 2017
www.ncbi.nhttps://www.ncbi.nlm.nih.gov/pubmed/28146421lm.nih.gov/pubmed/22357666

HDAC inhibitors enhance the immunotherapy response of melanoma cells.
Oncotarget
Date: 10 2017
https://www.ncbi.nlm.nih.gov/pubmed/29137331

Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis.
Case Rep Oncol Med.
Date: 12 2017
https://www.ncbi.nlm.nih.gov/pubmed/29445556